Coronary Artery Calcium (CAC) scoring serves as a vital diagnostic tool for assessing cardiovascular risk in patients with dyslipidemia and Cardiovascular-Kidney-Metabolic (CKM) syndrome. By quantifying calcified plaque in the coronary arteries, clinicians can better stratify risk beyond traditional lipid panels, allowing for more personalized preventive strategies and targeted lipid-lowering therapies in patients who fall into intermediate risk categories.
Understanding CKM Syndrome and Cardiovascular Risk
Cardiovascular-Kidney-Metabolic syndrome is a multisystem health condition characterized by the intersection of obesity, diabetes, chronic kidney disease, and cardiovascular disease. According to the American Heart Association, this integrated approach recognizes that these conditions share common biological pathways.
For patients managing dyslipidemia—an imbalance of lipids such as cholesterol and triglycerides—the presence of CKM syndrome complicates risk assessment. Traditional calculators, such as the ASCVD Risk Estimator, may not fully capture the cumulative damage caused by metabolic dysfunction. CAC scoring provides an objective measure of subclinical atherosclerosis, which can help physicians determine the urgency of initiating aggressive statin therapy.
The Role of Coronary Artery Calcium Scoring
A CAC score is derived from a non-contrast cardiac CT scan. The resulting score, known as the Agatston score, quantifies the extent of calcified plaque.
- 0: No identifiable plaque; very low risk.
- 1–99: Mild plaque; indicates the presence of atherosclerosis.
- 100–399: Moderate plaque; suggests significant disease.
- 400+: Severe plaque; high risk for future cardiac events.
Research published in the Journal of the American College of Cardiology indicates that CAC scoring is particularly useful for "reclassifying" patients who are considered to be at intermediate risk. If a patient with dyslipidemia has an elevated CAC score, it often serves as a "tie-breaker" that supports the initiation of pharmacologic intervention, even if their traditional risk scores suggest a lower threshold.
Clinical Implications for Dyslipidemia Management
Managing dyslipidemia in the context of CKM syndrome requires more than just lowering LDL-cholesterol. Clinicians must account for the inflammatory environment created by metabolic syndrome.
According to guidelines from the American College of Cardiology, the decision to use a CAC scan should be reserved for individuals where the need for statin therapy is uncertain. It is not intended for patients already at high risk who clearly require treatment, nor for those at very low risk.
Frequently Asked Questions
Who should consider a CAC scan?
The test is typically recommended for asymptomatic adults aged 40–75 who are at intermediate risk for cardiovascular disease and are uncertain about whether to start statin therapy.
Does a score of 0 mean I am free of heart disease?
A score of 0 indicates an absence of calcified plaque. However, it does not rule out the presence of non-calcified, soft plaque, which can still be vulnerable to rupture. It remains a strong negative predictor, meaning the likelihood of a major cardiac event in the near future is very low.
How often should a CAC scan be repeated?
Because calcium buildup is a slow process, repeat scans are generally not recommended for at least 3 to 5 years, unless there is a significant change in clinical status.
Future Directions in Risk Assessment
The integration of CAC scoring into the management of CKM syndrome represents a shift toward precision medicine. By identifying subclinical disease early, practitioners can implement lifestyle modifications and medical therapies before an acute event occurs. Future research aims to determine how emerging biomarkers for metabolic inflammation might further refine the predictive power of CAC scoring in patients with complex multisystem disorders.